1/16/2009 6:46:30 AM
PeHUB -- Hydra Biosciences, a Cambridge, Mas.-based developer of novel ion channel drugs, raised $22 million in Series D financing led by MedImmune Ventures. Prior investors contributing follow-on commitments include Advanced Technology Ventures, Abingworth, Polaris, BioVenture Investors, Biogen-Idec Ventures, and Lilly Ventures in the Series D round. Hydra Biosciences has raised $47 million in previous rounds of financing.
comments powered by